细胞衰老在肺癌微环境中的双向作用及其治疗意义

doi:10.3969/j.issn.1004-616x.2025.04.007

摘要/Abstract

摘要： 肺癌是全球癌症相关死亡的主要原因之一。研究表明，肿瘤微环境(TME)在肺癌的发生、发展及耐药过程中发挥关键作用，其中衰老细胞作为TME的重要组成部分，其作用备受关注。衰老最初被认为是一种抑制肿瘤发生的机制，然而，随着衰老细胞的积累，其衰老相关分泌表型(SASP)成分可促进肿瘤的生长、免疫逃逸及代谢重编程。此外，衰老T细胞、肿瘤相关巨噬细胞(TAMs)及成纤维细胞的功能变化进一步加剧了TME的免疫抑制状态，影响肺癌的进展及治疗效果。细胞衰老也对肺癌治疗有着双重治疗意义，如传统的抗癌策略化疗和放疗可诱导癌细胞衰老。但某些群体的衰老细胞可能长期存活并分泌SASP，促进炎症和肿瘤转移，清除衰老细胞或抑制SASP成为改善肺癌治疗效果的潜在方向。故本文对衰老细胞在肺癌中的双向作用以及细胞衰老的治疗意义进行综述。

关键词: 肺癌, 细胞衰老, 肿瘤微环境, 免疫衰老, 双向调节作用

中图分类号:

R734.2

智晓琛, 肖汀. 细胞衰老在肺癌微环境中的双向作用及其治疗意义[J]. 癌变·畸变·突变, 2025, 37(4): 284-287.

ZHI Xiaochen, XIAO Ting. The bidirectional role of cellular senescence in the lung cancer microenvironment and its therapeutic significance[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(4): 284-287.

参考文献

[1] LI Y T, YAN B S, HE S M. Advances and challenges in the treatment of lung cancer[J]. Biomed Pharmacother, 2023, 169: 115891.
[2] LEE J H, SAXENA A, GIACCONE G. Advancements in small cell lung cancer[J]. Semin Cancer Biol, 2023, 93: 123-128.
[3] MANSOURI S, HEYLMANN D, STIEWE T, et al. Cancer genome and tumor microenvironment: reciprocal crosstalk shapes lung cancer plasticity[J]. eLife, 2022, 11: e79895.
[4] CAMPISI J. Cellular senescence and lung function during aging. Yin and Yang[J]. Annals ATS, 2016, 13(Sup 5): S402-S406.
[5] GORGOULIS V, ADAMS P D, ALIMONTI A, et al. Cellular senescence: defining a path forward[J]. Cell, 2019, 179(4): 813-827.
[6] SCHNEIDER J L, ROWE J H, GARCIA-DE-ALBA C, et al. The aging lung: Physiology, disease, and immunity[J]. Cell, 2021, 184(8): 1990-2019.
[7] DOMEN A, DEBEN C, VERSWYVEL J, et al. Cellular senescence in cancer: clinical detection and prognostic implications[J]. J Exp Clin Cancer Res, 2022, 41(1): 360.
[8] RUHLAND M K, ALSPACH E. Senescence and immunoregulation in the tumor microenvironment[J]. Front Cell Dev Biol, 2021, 9: 754069.
[9] TAKASUGI M, YOSHIDA Y, OHTANI N. Cellular senescence and the tumour microenvironment[J]. Mol Oncol, 2022, 16(18): 3333-3351.
[10] TCHKONIA T, ZHU Y, VAN DEURSEN J, et al. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities[J]. J Clin Invest, 2013, 123(3): 966-972.
[11] COPPé J P, DESPREZ P Y, KRTOLICA A, et al. The senescence-associated secretory phenotype: the dark side of tumor suppression[J]. Annu Rev Pathol Mech Dis, 2010, 5: 99-118.
[12] DEMARIA M, O’LEARY M N, CHANG J H, et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse[J]. Cancer Discov, 2017, 7(2): 165-176.
[13] BATLLE E, MASSAGUé J. Transforming growth factor-β signaling in immunity and cancer[J]. Immunity, 2019, 50(4): 924-940.
[14] YANG X G, LIN Y L, SHI Y H, et al. FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling[J]. Cancer Res, 2016, 76(14): 4124-4135.
[15] COURAU T, NEHAR-BELAID D, FLOREZ L, et al. TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies[J]. JCI Insight, 2016, 1(9): e85974.
[16] FAGET D V, REN Q H, STEWART S A. Unmasking senescence: context-dependent effects of SASP in cancer[J]. Nat Rev Cancer, 2019, 19(8): 439-453.
[17] JHA S K, DE RUBIS G, DEVKOTA S R, et al. Cellular senescence in lung cancer: molecular mechanisms and therapeutic interventions[J]. Ageing Res Rev, 2024, 97: 102315.
[18] LOO T M, MIYATA K, TANAKA Y, et al. Cellular senescence and senescence-associated secretory phenotype via the cGAS-STING signaling pathway in cancer[J]. Cancer Sci, 2020, 111(2): 304-311.
[19] CRESPO J, SUN H Y, WELLING T H, et al. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment[J]. Curr Opin Immunol, 2013, 25(2): 214-221.
[20] ALSPACH E, LUSSIER D M, MICELI A P, et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy[J]. Nature, 2019, 574(7780): 696-701.
[21] SADIGHI AKHA A A. Aging and the immune system: an overview[J]. J Immunol Methods, 2018, 463: 21-26.
[22] RU K, CUI L, WU C, et al. Exploring the molecular and immune landscape of cellular senescence in lung adenocarcinoma[J]. Front Immunol, 2024, 15: 1347770.
[23] SUMITOMO R, HIRAI T, FUJITA M, et al. M2 tumor-associated macrophages promote tumor progression in non-small-cell lung cancer[J]. Exp Ther Med, 2019, 18(6): 4490-4498.
[24] HASTON S, GONZALEZ-GUALDA E, MORSLI S, et al. Clearance of senescent macrophages ameliorates tumorigenesis in KRAS-driven lung cancer[J]. Cancer Cell, 2023, 41(7): 1242-1260.e6.
[25] RUHLAND M K, LOZA A J, CAPIETTO A H, et al. Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis[J]. Nat Commun, 2016, 7: 11762.
[26] SHIN E, BAK S H, PARK T, et al. Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond[J]. Front Immunol, 2023, 14: 1192907.
[27] FORDER A, ZHUANG R, SOUZA V G P, et al. Mechanisms contributing to the comorbidity of COPD and lung cancer[J]. Int J Mol Sci, 2023, 24(3): 2859.
[28] BARNES P J, BAKER J, DONNELLY L E. Cellular senescence as a mechanism and target in chronic lung diseases[J]. Am J Respir Crit Care Med, 2019, 200(5): 556-564.
[29] HANSEL C, JENDROSSEK V, KLEIN D. Cellular senescence in the lung: the central role of senescent epithelial cells[J]. Int J Mol Sci, 2020, 21(9): 3279.
[30] ALTORKI N K, MARKOWITZ G J, GAO D C, et al. The lung microenvironment: an important regulator of tumour growth and metastasis[J]. Nat Rev Cancer, 2019, 19(1): 9-31.
[31] FANE M, WEERARATNA A T. How the ageing microenvironment influences tumour progression[J]. Nat Rev Cancer, 2020, 20(2): 89-106.
[32] LóPEZ-OTíN C, BLASCO M A, PARTRIDGE L, et al. Hallmarks of aging: an expanding universe[J]. Cell, 2023, 186(2): 243-278.
[33] BARTKOVA J, REZAEI N, LIONTOS M, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints[J]. Nature, 2006, 444(7119): 633-637.
[34] TEDESCHI V, PALDINO G, KUNKL M, et al. CD8⁺ T cell senescence: lights and shadows in viral infections, autoimmune disorders and cancer[J]. Int J Mol Sci, 2022, 23(6): 3374.
[35] LEE S, SCHMITT C A. The dynamic nature of senescence in cancer[J]. Nat Cell Biol, 2019, 21(1): 94-101.
[36] CHILDS B G, DURIK M, BAKER D J, et al. Cellular senescence in aging and age-related disease: from mechanisms to therapy[J]. Nat Med, 2015, 21(12): 1424-1435.
[37] CHIBAYA L, SNYDER J, RUSCETTI M. Senescence and the tumor-immune landscape: implications for cancer immunotherapy[J]. Semin Cancer Biol, 2022, 86(Pt 3): 827-845.
[38] RUSCETTI M, LEIBOLD J, BOTT M J, et al. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination[J]. Science, 2018, 362(6421): 1416-1422.
[39] KIRKLAND J L, TCHKONIA T. Senolytic drugs: from discovery to translation[J]. J Intern Med, 2020, 288(5): 518-536.
[40] ALEXA-STRATULAT T, PAVEL-TANASA M, CIANGA V A, et al. Immune senescence in non-small cell lung cancer management: therapeutic relevance, biomarkers, and mitigating approaches[J]. Expert Rev Anticancer Ther, 2022, 22(11): 1197-1210.
[41] AMOR C, FEUCHT J, LEIBOLD J, et al. Senolytic CAR T cells reverse senescence-associated pathologies[J]. Nature, 2020, 583(7814): 127-132.
[42] MENG J S, LI Y, WAN C, et al. Targeting senescence-like fibroblasts radiosensitizes non-small cell lung cancer and reduces radiation-induced pulmonary fibrosis[J]. JCI Insight, 2021, 6(23): e146334.